Investment Thesis — Centene Corporation
The market is mispricing Centene by fixating on its recent negative EPS and extreme short interest, overlooking the potential for a substantial earnings recovery in 2024 and the explosive short squeeze dynamics. This creates an asymmetric opportunity where a modest operational improvement could trigger a significant re-rating.
Catalysts
- Strong Q1/Q2 2024 earnings beat and positive guidance, signaling successful operational turnaround.
- Significant reduction in short interest, indicating capitulation from bearish investors and fueling a squeeze.
- Successful resolution of outstanding regulatory reviews or litigation, removing a key overhang.
Risk Factors
- Failure to execute on the 2024 earnings recovery plan, leading to continued losses and cash burn.
- Adverse regulatory changes or increased scrutiny on managed care organizations, impacting profitability.
- Further deterioration of medical loss ratio or member churn exceeding expectations, pressuring margins.
Key Debates
Divestiture headwind ends, Fwd Rev Growth turns positive 1% by H1 2025
Net Margin turns positive to 1% by Q3 2024, re-rating P/E
CNC price reaches Analyst PT of $45.50 by Q4 2024